Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) Equity Average (2016 - 2025)

Historic Equity Average for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to $18.7 million.

  • Aytu Biopharma's Equity Average fell 3832.09% to $18.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $18.7 million, marking a year-over-year decrease of 3832.09%. This contributed to the annual value of $23.3 million for FY2025, which is 3040.12% down from last year.
  • Latest data reveals that Aytu Biopharma reported Equity Average of $18.7 million as of Q4 2025, which was down 3832.09% from $21.1 million recorded in Q3 2025.
  • Aytu Biopharma's 5-year Equity Average high stood at $140.4 million for Q2 2021, and its period low was $18.7 million during Q4 2025.
  • Moreover, its 5-year median value for Equity Average was $37.9 million (2023), whereas its average is $55.1 million.
  • Per our database at Business Quant, Aytu Biopharma's Equity Average surged by 3385.14% in 2021 and then plummeted by 6279.89% in 2022.
  • Aytu Biopharma's Equity Average (Quarter) stood at $108.5 million in 2021, then crashed by 56.61% to $47.1 million in 2022, then crashed by 30.95% to $32.5 million in 2023, then fell by 6.81% to $30.3 million in 2024, then plummeted by 38.32% to $18.7 million in 2025.
  • Its Equity Average was $18.7 million in Q4 2025, compared to $21.1 million in Q3 2025 and $26.9 million in Q2 2025.